دوره 3، شماره 8 - ( 11-1395 )                   جلد 3 شماره 8 صفحات 46-53 | برگشت به فهرست نسخه ها


XML English Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Lyman D. B cell Therapy to Treat an Axonal Neuropathy in Mixed Connective Tissue Disease . Caspian.J.Neurol.Sci. 2017; 3 (8) :46-53
URL: http://cjns.gums.ac.ir/article-1-154-fa.html
B cell Therapy to Treat an Axonal Neuropathy in Mixed Connective Tissue Disease . مجله علوم اعصاب کاسپین. 1395; 3 (8) :46-53

URL: http://cjns.gums.ac.ir/article-1-154-fa.html


چکیده:   (933 مشاهده)

The B cell is a vital contributor to humoral immunity. The B cell-specific antigen CD20 is expressed during B cell development, starting at the pre-B cell level and persists through B cell differentiation, but is lost during terminal differentiation to plasma cells.

Rituximab is a monoclonal antibody that destroys both normal and malignant B cells that have CD20 on their surfaces and is therefore used to treat diseases characterized by excessive B cells, overactive B cells, or dysfunctional B cells.

The connective tissue diseases and vasculitis mediated by B cell may cause various disorders of the peripheral nervous system especially axonal neuropathy. B cell–directed therapies may represent a promising new treatment for autoimmune axonal neuropathies.

متن کامل [PDF 587 kb]   (445 دریافت)    
نوع مطالعه: مروری | موضوع مقاله: تخصصي
دریافت: ۱۳۹۶/۱/۲۴ | پذیرش: ۱۳۹۶/۱/۲۴ | انتشار: ۱۳۹۶/۱/۲۴

ارسال نظر درباره این مقاله : نام کاربری یا پست الکترونیک شما:
CAPTCHA code

کلیه حقوق این وب سایت متعلق به مجله علوم اعصاب کاسپین می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2018 All Rights Reserved | Caspian Journal of Neurological Sciences

Designed & Developed by : Yektaweb